Markets
markets
Luke Kawa

POET Technologies tumbles after announcing $150 million share offering to two new fundamental investment managers

POET Technologies is tumbling after announcing that it’s selling 20.7 million shares to raise approximately $150 million in an oversubscribed registered direct offering “by two new fundamental investors.”

Its prior $75 million raise through the sale of stock and warrants earlier this month is widely presumed to have been to MMCAP International, which was already its largest shareholder.

“We’ve been very pleased with the level of interest in POET by investors of all types — retail, institutional,” POET Executive Chairman and CEO Dr. Suresh Venkatesan recently told Sherwood News, saying that the company’s focus this year is to make sure that “the technology that we’re developing is truly manufacturable at scale and at wafer scale.”

The optical communications company has enjoyed elevated interest from retail investors recently as the AI boom raises the demand for data to be transferred as quickly and efficiently as possible. Last week, POET announced a $5 million order for its optical engines from a “leading systems integrator.”

Per the press release, POET “intends to use the net proceeds from this investment for corporate development, including targeted acquisitions, scaling up of R&D, acceleration of the light source business, expanding operations, and general working capital.”

More Markets

See all Markets
markets

Globalstar surges after FT reports that Amazon is in talks to buy the satellite group

Globalstar is up 11% in premarket trading on Thursday on reports that Amazon is in talks to buy the satellite company, in a push to take on Elon Musk's SpaceX. The two companies are currently negotiating the details of a potential deal after lengthy talks, the Financial Times reported, citing people familiar with the matter.

Amazon has ambitions to compete with Elon Musk's SpaceX to provide satellite-based internet access anywhere on the planet — a market which is dominated by Starlink at the moment and is a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing on its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation with has some 10,000 active satellites.

But Amazon’s not the only big tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, per Bloomberg last October.

Globalstar's stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

Amazon has ambitions to compete with Elon Musk's SpaceX to provide satellite-based internet access anywhere on the planet — a market which is dominated by Starlink at the moment and is a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing on its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation with has some 10,000 active satellites.

But Amazon’s not the only big tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, per Bloomberg last October.

Globalstar's stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

markets

FDA clarifies stricter stance on GLP-1 compounding: Reuters

The Food and Drug Administration reiterated its increasingly strict stance on compounded versions of GLP-1s, Reuters reported Wednesday.

The FDA said that, outside of drug shortages, “routine production” of copycat drugs is not allowed. Producing the compounded versions could now “prompt enforcement action,” Reuters reported.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.